Abivax SA (ABVX) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Abivax SA (ABVX) right now is Positive Phase 3 obefazimod data: Both ABTECT induction trials and the maintenance trial met their primary endpoints, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% on placebo. Product revenue (TTM) is ~negligible (pre-commercial). If that keeps playing out, the setup is favourable; the risk to it is as a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. No one can predict where ABVX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Abivax SA (ABVX) higher?
1. Positive Phase 3 obefazimod data
Both ABTECT induction trials and the maintenance trial met their primary endpoints, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% on placebo. The data positioned obefazimod as a competitive oral option in ulcerative colitis and drove a sharp re-rating of the shares in mid-2026.
2. Path to an FDA filing
Management has guided toward submitting a U.S. new drug application for obefazimod in ulcerative colitis around Q4 2026. A regulatory filing and any eventual approval would be the key milestones that convert a clinical-stage story into a potential commercial one.
3. Pipeline expansion into Crohn's disease
Beyond ulcerative colitis, Abivax is running a Phase 2b induction study of obefazimod in Crohn's disease, with data guided to around mid-2027. A second large indication would broaden the addressable market for the same molecule and diversify the single-asset dependence somewhat.
4. Strengthened balance sheet
An upsized, oversubscribed U.S. ADS offering priced at $125 raised roughly $800M and extended the projected cash runway into 2029. That funding is meant to carry the company through the FDA filing and potential U.S. commercialization without an immediate need to raise again.
What could weigh on ABVX?
As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Malignancy signals at the 50 mg dose have been a focal regulatory question, even though integrated safety data reported rates in line with background disease incidence. The ulcerative colitis market is crowded with established therapies such as Rinvoq, Skyrizi, Zeposia, and Entyvio, so commercial success is not guaranteed even after approval. The company generates negligible revenue and large net losses, and repeated equity raises have diluted shareholders. Approval, launch execution, and any partnership or acquisition outcome all remain uncertain.
Where ABVX trades today
A forecast starts from where the stock actually is. These are ABVX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ABVX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ABVX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ABVX guide and whether ABVX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ABVX outlook
The bottom line: what is driving Abivax SA (ABVX) is Positive Phase 3 obefazimod data, with product revenue (ttm) at ~negligible (pre-commercial). If that keeps playing out the setup is favourable; the risk is as a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. No one can predict the price, so treat any ABVX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ABVX with Walnut
Use Abivax SA as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Abivax SA (ABVX)?
+
No one can reliably predict where ABVX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Abivax SA higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ABVX higher?
+
The main growth drivers are Positive Phase 3 obefazimod data; Path to an FDA filing; Pipeline expansion into Crohn's disease. Whether they play out is the real question, not a guaranteed path.
What are the risks to ABVX?
+
As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Malignancy signals at the 50 mg dose have been a focal regulatory question, even though integrated safety data reported rates in line with background disease incidence. The ulcerative colitis market is crowded with established therapies such as Rinvoq, Skyrizi, Zeposia, and Entyvio, so commercial success is not guaranteed even after approval. The company generates negligible revenue and large net losses, and repeated equity raises have diluted shareholders. Approval, launch execution, and any partnership or acquisition outcome all remain uncertain.
Will ABVX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Abivax SA's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ABVX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ABVX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.